AUTONOMOUS DIAGNOSTIC
SCREENING REDEFINED
CAUTION: Federal (US) law restricts this device to investigational use only. NOT SOLD in the US.
OUR RESEARCH
PROSPECTIVE CLINICAL STUDY FOR THE DETECTION OF MORE-THAN-MILD DIABETIC RETINOPATHY
Images from two fundus cameras were evaluated in a multisite study - a desktop camera (Topcon NW400) and a handheld camera (Optomed Aurora). One image per eye was obtained from each patient. Images were analyzed using AEYE Health’s AI-based system. The results of AEYE’s system were compared to results obtained from a panel of experts.
TOPCON NW400
93.0%
Sensitivity
>99%
Imageability
91.4%
Specificity
1 Image
Per eye
OPTOMED AURORA
91.9%
Sensitivity
>99%
Imageability
93.6%
Specificity
1 Image
Per eye
CAUTION: Federal (US) law restricts this device to investigational use only. NOT SOLD in the US.
OUR VISION
ACCURATE AI-BASED DIAGNOSTIC SCREENING THAT IS AFFORDABLE AND ACCESSIBLE
.png)
ACCURATE
Observed in a prospective pivotal clinical trial
PRACTICAL
Single image from each eye
Works with a cost-effective
handheld camera
Real-time diagnosis
.png)
BROAD SCREENING
Broad multi-indication research platform
HOW IT WORKS
01
A single image
is obtained from each eye
02
Images are analyzed using AEYE’s software
03
A diagnostic report is generated within a minute
CAUTION: Federal (US) law restricts this device to investigational use only.
NOT SOLD in the US.
OUR TEAM
WE ARE LEADERS IN AI-BASED DIAGNOSTIC SCREENING FOR RETINAL DISEASES
ZACK DVEY-AHARON, PHD
CEO, Co-Founder
Serial entrepreneur, advisor,
lecturer. Ph.D. in ML, 8200
DANNY MARGALIT
COO, Co-Founder
Co-Founder Aladdin (NASDAQ IPO)
Product & IP Expert
AMIT WOHL
VP Product & Marketing
Seasoned technology expert
MSc, MBA MIT, BSc Technion
Think you are a great fit but didn't find a position that matches your skills?
Send your CV to careers@aeyehealth.com
CAREERS
